Related Experiment Video
Updated: Sep 3, 2026
Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay
Published on: April 15, 2014
Implication of ornithine decarboxylase and polyamines in pancreatic growth of neonatal rats
Insights
Alpha-difluoromethylornithine (DFMO) inhibits pancreatic growth in neonatal rats by affecting polyamine synthesis. This study shows DFMO impacts pancreatic weight and DNA, highlighting ODC
Area of Science:
- Developmental Biology
- Biochemistry
- Pharmacology
Background:
- Ornithine decarboxylase (ODC) is a key enzyme in polyamine synthesis.
- Polyamines are essential for cell growth and proliferation.
- The role of ODC in neonatal pancreatic development requires further investigation.
Purpose of the Study:
- To investigate the effects of alpha-difluoromethylornithine (DFMO) on pancreatic growth and development in newborn rats.
- To determine the impact of DFMO, an ODC inhibitor, on pancreatic weight, cellular composition, and enzyme content.
Main Methods:
- Neonatal rats received daily subcutaneous injections of DFMO (300 or 500 mg/kg).
- Pancreatic tissues were analyzed at 7, 14, 21, and 28 days post-treatment.
- Measurements included pancreatic weight, DNA, RNA, protein, amylase, and chymotrypsin content and concentration.
Main Results:
- DFMO significantly inhibited body weight gain and pancreatic growth in a dose- and time-dependent manner.
- Pancreatic DNA content was reduced by DFMO, with maximal reduction observed at higher doses and longer treatment durations.
- Chymotrypsin levels were more affected by DFMO than amylase levels, suggesting differential regulation.
Conclusions:
- ODC and polyamines play a crucial role in neonatal pancreatic cell replication and growth.
- DFMO effectively inhibits pancreatic development by targeting the ODC pathway.
- These findings provide insights into the biochemical regulation of pancreatic development during the neonatal period.
Abstract:
The current study examines the effects of alpha-difluoromethylornithine (DFMO), an irreversible ornithine decarboxylase inhibitor, on pancreatic growth and development of rat neonates. Newborn rats were given daily subcutaneous injections of 300 or 500 mg kg-1 DFMO and killed after 7, 14, 21, and 28 days of treatment. Pancreatic weights and DNA, RNA, protein, amylase and chymotrypsin total contents (per pancreas) and concentrations were evaluated at the end of each period. Inhibition of body weight gain (30%) was maximal after 14 days of the 500 mg DFMO treatment. Pancreatic weight increase of 20% was significant after 7 days of the 300 mg DFMO treatment while deficits of 15, 20, and 14% were significant after 21 days of 300 mg DFMO and 14 and 21 days of 500 mg DFMO. Total DNA was already subnormal after one week of 500 mg DFMO with a maximal reduction of 30% after 28 days while a significant decrease of 15% was observed only after 3 weeks of 300 mg DFMO. Pancreatic hypertrophy was observed after 7 and 28 days of the 500 mg and after 14 days of the 300 mg DFMO treatment. Chymotrypsin total contents and concentrations were always preferentially affected over those of amylase. These data support the view that ornithine decarboxylase (ODC) and polyamines play an important role in cell replication and growth of the pancreatic tissue during the neonatal period.
More Related Videos
07:44Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation
Published on: August 7, 2015
09:12Assessing Cellular Stress and Inflammation in Discrete Oxytocin-secreting Brain Nuclei in the Neonatal Rat Before and After First Colostrum Feeding
Published on: November 14, 2018